iCardiac Technologies, Inc, provides drug development companies worldwide with the complete range of core lab services. Its team of cardiac safety experts collectively bring over 100 years of cardiology, electrophysiology, drug development, regulatory and academic experience. The iCardiac team pioneered the field of autonomic nervous system effects on the QT interval, a phenomenon estimated to produce false-positive results in conventional QT studies for as many as 25% of all molecules currently in clinical development. iCardiac team members are active contributors on several FDA working groups that are advancing the field of cardiac safety.